In an adult with basal cell carcinoma, carotid stenosis, chronic atrial fibrillation, hyperlipidemia, hypertension, prostate cancer, and obstructive sleep apnea (AHI 34, residual AHI 1.1 on PAP therapy) who takes mirtazapine 22.5 mg at bedtime but continues to awaken at night, what alternative sleep‑aid medications are appropriate?

Alternative Sleep Medications for Nocturnal Awakenings in OSA Patient on Mirtazapine

For this patient with well-controlled OSA (residual AHI 1.1) experiencing nocturnal awakenings despite mirtazapine 22.5 mg, switch to low-dose doxepin (3-6 mg) or suvorexant (10-20 mg) as these are the only evidence-based options specifically recommended for sleep maintenance insomnia.

Clinical Context and Reasoning

Your patient's OSA is excellently controlled on PAP therapy (AHI reduced from 34 to 1.1), so the nocturnal awakenings represent true insomnia rather than untreated sleep apnea. The mirtazapine is failing to address sleep maintenance issues despite being at a reasonable dose.

Why Mirtazapine May Be Failing

Mirtazapine causes significant somnolence (54% of patients in trials) 1 and is associated with substantial weight gain (7.5% of patients gained ≥7% body weight) 1, which could paradoxically worsen OSA over time. Importantly, research shows that promising preliminary mirtazapine results for OSA failed to be reproduced in larger multicentre trials, and its use was associated with significant weight gain and sleepiness 2. The drug is FDA-approved for depression, not insomnia, and should be tapered gradually to avoid withdrawal symptoms 1.

Evidence-Based Alternatives

First-Line Recommendation: Low-Dose Doxepin

Doxepin 3-6 mg is specifically recommended for sleep maintenance insomnia 333. This is critical because your patient's problem is nocturnal awakenings (sleep maintenance), not sleep onset.

Advantages in this patient:

• Targets sleep maintenance specifically
• Low doses (3-6 mg) minimize anticholinergic effects
• No respiratory depression concerns with OSA
• Does not cause significant weight gain
• AASM guideline-supported (weak recommendation, but positive) 3

Second-Line Option: Suvorexant

Suvorexant 10-20 mg is the only orexin receptor antagonist recommended specifically for sleep maintenance insomnia 33.

Advantages:

• Novel mechanism (orexin antagonism) different from mirtazapine
• Specifically studied for sleep maintenance
• May be safer in OSA patients (no respiratory depression)
• AASM weak recommendation for sleep maintenance 3

Other Guideline-Supported Options (with caveats)

Eszopiclone 2-3 mg or zolpidem 10 mg are recommended for both sleep onset AND maintenance 333, but require caution:

• Critical FDA warning: Risk of serious injuries from complex sleep behaviors (sleepwalking, sleep driving) 4
• Use lowest effective dose for shortest duration
• In this patient with cardiovascular disease (atrial fibrillation, carotid stenosis), fall risk from these agents is concerning
• Better suited for younger, healthier patients

What NOT to Use

Avoid trazodone - The AASM explicitly recommends AGAINST trazodone for insomnia 333. Despite being commonly prescribed off-label, it showed no difference from placebo in sleep efficiency and had an unfavorable adverse effect profile 4.

Avoid benzodiazepines (temazepam, triazolam) - While they have weak AASM recommendations 3, the VA/DoD guidelines advise AGAINST them due to:

• Risk of dependency and diversion
• Falls and cognitive impairment (especially concerning with this patient's age and cardiovascular disease)
• Hypoventilation risk in patients with respiratory conditions including sleep apnea 4
• Harms substantially outweigh benefits 4

Avoid antihistamines (diphenhydramine) - AASM recommends against use 33, and tolerance develops after 3-4 days 4. The 2019 Beers Criteria carry a strong recommendation to avoid in older adults due to antimuscarinic effects 4.

Avoid melatonin, valerian, L-tryptophan - All have negative AASM recommendations 33.

Special Considerations for This Patient

Cardiovascular Risk Factors

With chronic atrial fibrillation, carotid stenosis, and hypertension, this patient needs careful medication selection:

• Mirtazapine can cause QT prolongation, especially in overdose or with other QT-prolonging drugs 1
• Low-dose doxepin has minimal cardiac effects at 3-6 mg doses
• Avoid medications that increase fall risk (benzodiazepines, high-dose sedatives)

OSA Considerations

The patient's OSA is well-controlled (residual AHI 1.1), but:

• Weight gain from mirtazapine could worsen OSA over time 1
• Respiratory depressants (benzodiazepines) are contraindicated 4
• Continue monitoring PAP compliance and efficacy

Drug Interactions

Review for:

• CYP3A4 inhibitors/inducers that may affect mirtazapine levels 1
• QT-prolonging medications (antibiotics, antipsychotics) 1
• Other CNS depressants - avoid combining benzodiazepines with any new sleep medication 11

Practical Implementation

Recommended approach:

1. Taper mirtazapine gradually over 1-2 weeks to avoid withdrawal 1
2. Start doxepin 3 mg at bedtime (can increase to 6 mg if needed after 1-2 weeks)
3. Alternative: Start suvorexant 10 mg (can increase to 15-20 mg if inadequate response)
4. Reassess in 2-4 weeks for efficacy and tolerability
5. Monitor weight - any medication causing weight gain risks worsening OSA

If neither works: Consider cognitive behavioral therapy for insomnia (CBT-I) as the gold standard non-pharmacologic approach, or re-evaluate for other causes of nocturnal awakenings (nocturia, pain, anxiety, medication effects).

Common Pitfalls to Avoid

• Don't continue mirtazapine indefinitely if it's not working - it causes weight gain that could worsen OSA 12
• Don't use trazodone despite its popularity - evidence doesn't support it 34
• Don't prescribe benzodiazepines in OSA patients - respiratory depression risk 4
• Don't abruptly stop mirtazapine - taper to avoid withdrawal 1
• Don't ignore PAP adherence - ensure the insomnia isn't from mask discomfort or pressure intolerance